Leerink Partnrs Decreases Earnings Estimates for NeoGenomics

NeoGenomics, Inc. (NASDAQ:NEO) – Equities researchers at Leerink Partnrs lowered their Q1 2025 earnings per share estimates for NeoGenomics in a research report issued on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings of ($0.07) per share for the quarter, down from their prior estimate of ($0.02). The consensus estimate for NeoGenomics’ current full-year earnings is ($0.16) per share. Leerink Partnrs also issued estimates for NeoGenomics’ Q2 2025 earnings at ($0.03) EPS, Q4 2025 earnings at $0.01 EPS, FY2025 earnings at ($0.10) EPS and FY2026 earnings at $0.07 EPS.

A number of other analysts have also commented on the company. Benchmark lowered NeoGenomics from a “buy” rating to a “hold” rating in a research report on Monday, January 13th. Jefferies Financial Group started coverage on NeoGenomics in a report on Tuesday, December 10th. They set a “buy” rating and a $22.00 price objective for the company. Bank of America increased their target price on NeoGenomics from $18.00 to $19.00 and gave the stock a “neutral” rating in a report on Friday, December 13th. Finally, Needham & Company LLC restated a “buy” rating and set a $19.00 price target on shares of NeoGenomics in a research note on Friday, January 10th. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, NeoGenomics presently has a consensus rating of “Moderate Buy” and an average target price of $20.30.

NeoGenomics Price Performance

Shares of NASDAQ NEO opened at $14.86 on Thursday. The firm has a market capitalization of $1.91 billion, a P/E ratio of -24.36 and a beta of 1.24. The firm’s 50-day moving average price is $16.53 and its 200-day moving average price is $15.68. The company has a current ratio of 1.99, a quick ratio of 1.91 and a debt-to-equity ratio of 0.37. NeoGenomics has a 1-year low of $12.13 and a 1-year high of $19.11.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.04. The company had revenue of $167.80 million during the quarter, compared to analyst estimates of $167.00 million. NeoGenomics had a negative net margin of 12.07% and a negative return on equity of 2.11%. NeoGenomics’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.06) EPS.

Insiders Place Their Bets

In other news, General Counsel Alicia C. Olivo sold 5,175 shares of the company’s stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $15.36, for a total value of $79,488.00. Following the completion of the transaction, the general counsel now directly owns 37,129 shares of the company’s stock, valued at $570,301.44. This represents a 12.23 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 1.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Versant Capital Management Inc raised its holdings in shares of NeoGenomics by 174.9% in the 4th quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company’s stock worth $30,000 after purchasing an additional 1,142 shares during the period. Quarry LP bought a new stake in shares of NeoGenomics in the third quarter valued at $40,000. Blue Trust Inc. raised its stake in shares of NeoGenomics by 42.3% in the third quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock valued at $46,000 after buying an additional 987 shares during the period. Canada Pension Plan Investment Board purchased a new position in shares of NeoGenomics during the 2nd quarter valued at $57,000. Finally, KBC Group NV grew its stake in shares of NeoGenomics by 33.1% during the 3rd quarter. KBC Group NV now owns 4,530 shares of the medical research company’s stock worth $67,000 after acquiring an additional 1,127 shares during the period. Hedge funds and other institutional investors own 98.50% of the company’s stock.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.